Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All camostat studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCamostatCamostat (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19

Parsonnet et al., NCT04524663, COPS-2003, NCT04524663
May 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Progression -392% Improvement Relative Risk Recovery 35% Serious adverse events 86% Viral clearance 41% Camostat  COPS-2003  EARLY TREATMENT  DB RCT Is early treatment with camostat beneficial for COVID-19? Double-blind RCT 49 patients in the USA Higher progression (p=0.49) and improved recovery (p=0.24), not sig. c19early.org Parsonnet et al., NCT04524663, May 2021 Favorscamostat Favorscontrol 0 0.5 1 1.5 2+
RCT 49 outpatients in the USA, showing no significant differences with camostat treatment.
risk of progression, 392.0% higher, RR 4.92, p = 0.49, treatment 2 of 25 (8.0%), control 0 of 24 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no recovery, 35.0% lower, HR 0.65, p = 0.24, treatment 25, control 24, Cox proportional hazards.
serious adverse events, 86.0% lower, RR 0.14, p = 0.11, treatment 0 of 25 (0.0%), control 3 of 24 (12.5%), NNT 8.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no viral clearance, 40.8% lower, HR 0.59, p = 0.24, treatment 25, control 24, inverted to make HR<1 favor treatment, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Parsonnet et al., 15 May 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04524663 (history) (COPS-2003). Contact: parsonnt@stanford.edu.
This PaperCamostatAll
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit